News

71. Cara Therapeutics Initiates Phase I Study With Oral Formulation Of Novel Peripherally-Acting Kappa Opioid Agonist 11/23/2011
    Cara Therapeutics, Inc. today announced the initiation of a first-in-man Phase I clinical trial of an oral formulation of its peptide-based, kappa opioid agonist, CR845, in healthy volunteers.
72. INC Research, SAS Collaborate To Improve Clinical Trials Outcomes 11/17/2011
    INC Research, a therapeutically focused clinical research organization (CRO) with a Trusted Process for delivering reliable results, and SAS are working together to improve clinical development risk management and achieve targeted product profiles through analytics.
73. Clinical Hold Removed For Helix Biopharma Corp.'s Topical Interferon Alpha-2B Phase II/III Efficacy Trial IND Application 11/14/2011
    Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that the “clinical hold” on its investigational new drug (“IND”) application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the United States Food and Drug Administration (“FDA”).
74. Highly Anticipated Drugs From BioSante And AEterna Zentaris May Not Be As Lucrative As Expected 11/10/2011
    Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation and shockingly disappointing earnings elicit large movements in stock prices.
75. ClinStar To Present On Clinical Trial Recruitment In The Emerging Regions Of Russia And Eastern Europe 11/2/2011
    ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced recently that President and CEO David Passov and Manager of Clinical Operations Alexander Kutermin will speak at Global Engage's 3rd Oncology Clinical Trials in Emerging Regions conference, November 3-4, in Philadelphia, PA.
76. Novartis Achieves Strong Third Quarter Financial Performance And Pipeline Progress 10/28/2011
    Novartis is announcing recently additional cost reduction activity, which will be executed over three to five years. Elements of the activity to include: reallocation of production within the Novartis network resulting in closure of two sites in Switzerland and one in Italy; restructuring the development organization largely in Switzerland and the US and relocating some research activities from Switzerland to the US.
77. Linking Of Mutations In 12 Genes To Ovarian Cancer May Lead To More Effective Prevention 10/28/2011
    The study used a quick, accurate genome sequencing method that could become a single test to screen for a broad range of cancers.
78. Del Mar Pharmaceuticals Initiates Glioblastoma Clinical Trial 10/27/2011
    DelMar Pharmaceuticals today announced the initiation of the Company's planned clinical trial with its lead drug candidate, VAL-083, for the treatment of refractory glioblastoma multiforme (GBM).
79. Agilent Technologies Supports Research At The Broad Institute, Developing Proteomics Technology To Detect Disease Biomarkers 10/13/2011
    Agilent Technologies Inc. and the Agilent Technologies Foundation recently announced that Steven Carr, Ph.D, who directs the Proteomics Platform at the Broad Institute of MIT and Harvard, has been selected for an Agilent Thought Leader Award supporting his work developing new technology for analyzing proteins and peptides.
80. Virus Kills Breast Cancer Cells In Laboratory 9/27/2011
    A non-disease causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to Penn State College of Medicine researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.